Mitochondrial-Encoded Peptide MOTS-c, Diabetes, and Aging-Related Diseases

As our understanding of mitochondrial biology deepens, a new class of signaling molecules — mitochondrial-derived peptides — has emerged as critical regulators of metabolic health. This review by Kong, Lee, and Cho, published in Diabetes & Metabolism Journal, examined the growing body of evidence on MOTS-c's role in diabetes and aging-related diseases.

The authors compiled and analyzed research spanning preclinical studies and emerging human data on MOTS-c's mechanisms of action, its effects on glucose metabolism and insulin sensitivity, and its potential therapeutic applications for age-related metabolic conditions. They explored how MOTS-c functions as a retrograde signal from mitochondria to the nucleus.

The evidence presented confirms MOTS-c as a powerful metabolic regulator with broad protective effects. The peptide improves insulin sensitivity, enhances glucose uptake, reduces inflammation, and modulates cellular stress responses. These effects extend beyond diabetes to encompass a range of aging-related conditions where mitochondrial dysfunction plays a role.

For the field of peptide therapeutics, this review reinforces MOTS-c's position as one of the most promising mitochondrial-derived peptides. Its natural origin as an endogenous signaling molecule, combined with its broad metabolic benefits and favorable safety profile, makes it an attractive candidate for addressing the metabolic decline that accompanies aging.